References
- National Osteoporosis Foundation. Fast facts of osteoporosis. Available at: http://www.nof.org/osteoporosis/diseasefacts.htm#prevalence [Last accessed 11 December 2009]
- Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007;22:465-75
- US Dept of Health and Human Services Office of the Surgeon General. Bone Health and Osteoporosis: A Report of the Surgeon General, 2004. Available at: http://www.surgeongeneral.gov/library/bonehealth/docs/full_report.pdf [last accessed 11 December 2009]
- Top 200 Brand Drugs by Units in 2007. Drug Topics, 2008. Available at: http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/072008/491207/article.pdf [last accessed 11 December 2009]
- MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197-213
- Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008:CD001155
- Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008:CD004523
- Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006;119:S18-24
- Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003;14:259-62
- Barrett-Connor E, Ensrud K, Tosteson AN, et al. Design of the POSSIBLE USTM Study: postmenopausal women’s compliance and persistence with osteoporosis medications. Osteoporos Int 2009;20:463-72
- Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72
- Silverman SL. The osteoporosis assessment questionnaire (OPAQ): a reliable and valid disease-targeted measure of health related quality of life (HRQoL) in osteoporosis. Qual Life Res 2000;9:767-74
- Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004;2:12
- Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002;77:262-70
- Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000;160:517-25
- Grima D, Ioannidis G, Papaioannou A, et al. Treatment discontinuation due to gastrointestinal adverse events and decreased bone mineral density in patients switched from branded alendronate to generic alendronate. J Bone Miner Res 2008;23(S1):S210
- Ringe JD, Moller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 2009:30:213-21
- Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12:1-12
- Harris ST, Watts NB, Li Z, et al. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004;20:757-64